BioRestorative Therapies develops stem cell treatments for chronic back pain caused by disc degeneration.
Here are five things to know:
1. The company's BRTX-100 is a novel autologous stem cell product to designed to treat degenerative disc disease.
2. In February 2017, BioRestorative received FDA clearance to begin a phase 2 clinical trial of BRTX-100.
3. The phase 2 trial is expected to start in the first quarter of 2019.
4. The company appointed Wayne J. Olan, MD, as clinical director of its regenerative disc/spine program.
5. BioRestorative also developed the ThermoStem program to treat metabolic disorders, including diabetes and obesity.